Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 2/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 2/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 2/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 2/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 2/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 2/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 2/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
| ▸ | GABRE | P78334 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 1/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonipecotic Acid SCHEMBL104297 | 1.00 | — | — | |
| Isonipecotic Acid SCHEMBL5035880 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL30060745 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL11556866 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL6122239 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL23043998 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL2560208 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL31602943 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL1703706 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 | |
| Isonipecotic Acid SCHEMBL28089924 | 0.97 | TSHR (0.94) | TSHRGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| EP-3158053-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | St. George's Hospital Medical School (GB) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193688-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2015-12-23 | — | — | WO | disclosed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | disclosed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | disclosed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| WO-2011123654-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS OF PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | COLUCID PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110195238-A1 | ANTHRAPYRIDONE COLORING MATTER, SALT THEREOF, INK COMPOSITION AND COLORED BODY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195238-A1 | ANTHRAPYRIDONE COLORING MATTER, SALT THEREOF, INK COMPOSITION AND COLORED BODY | XDH, HAX1, ANXA1 | TSHR 3438/4885GABRA1 4292/4885GABRG2 4554/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | TSHR 28/4885GABRA1 916/4885GABRG2 1444/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | TSHR 28/4885GABRA1 916/4885GABRG2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.